{"disease":{"id":"family","name":"family"},"drugs":{"marketed":[{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tafamidis-reference","indication_name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis (Reference)","generic_name":"tafamidis-reference","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TTR protein","drug_class":"Stabilizer","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"busilvex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"busulfex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":87,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06440447","title":"EXploring Patterns of Use and Effects of Adult Day Programs to Improve Trajectories of Continuing CarE","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500000,"lead_sponsor_name":"York University","has_results":false},{"nct_id":"NCT04471701","title":"Italian Web-based Cross-sectional Survey on COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Institute of Biomedical Technologies-National Research Council, Italy","has_results":false},{"nct_id":"NCT03971344","title":"Impact of Serious Pediatric Illness on Parent and Sibling Health","phase":"","overall_status":"COMPLETED","enrollment_count":161000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT05045599","title":"Effectiveness of Integrating Family Planning - Maternal, Newborn and Child Health (MNCH) Services on Uptake of Voluntary Modern Contraceptive Methods","phase":"NA","overall_status":"UNKNOWN","enrollment_count":125000,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT03106727","title":"Evaluating the Impact of a Community Health Worker Program in Neno, Malawi","phase":"NA","overall_status":"COMPLETED","enrollment_count":122395,"lead_sponsor_name":"Partners in Health","has_results":false},{"nct_id":"NCT06786871","title":"ARTLifeLine: Assisted Reproduction Technology (ART) Family Health and Development Trajectory Cohort (ARTLL)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07158983","title":"Evaluation of a Child Health Care Program for Early Identification of Family Violence","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":90000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05056545","title":"Postpartum Family Planning Program in Rwanda","phase":"NA","overall_status":"COMPLETED","enrollment_count":42377,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04145388","title":"Family History Study on Cancer Risk","phase":"NA","overall_status":"UNKNOWN","enrollment_count":18623,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT03799185","title":"Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population","phase":"","overall_status":"COMPLETED","enrollment_count":13610,"lead_sponsor_name":"Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose","has_results":false},{"nct_id":"NCT07048236","title":"Specimen and Clinical Data Collection Plan for LDCT Screening Participants","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Chung Shan Medical University","has_results":false},{"nct_id":"NCT03875586","title":"Consultation Reasons in Family Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":10822,"lead_sponsor_name":"Dacima Consulting","has_results":false},{"nct_id":"NCT03472300","title":"Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9600,"lead_sponsor_name":"Frederiksberg University Hospital","has_results":false},{"nct_id":"NCT03333473","title":"Postpregnancy Family Planning Choices in Public and Private Sectors in Kenya and Indonesia","phase":"NA","overall_status":"COMPLETED","enrollment_count":9282,"lead_sponsor_name":"Jhpiego","has_results":false},{"nct_id":"NCT07200648","title":"Basic Income Guaranteed: Los Angeles Economic Assistance Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":8194,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04040270","title":"Family Drama Project","phase":"NA","overall_status":"COMPLETED","enrollment_count":7453,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04048915","title":"Family Drama Project II","phase":"NA","overall_status":"COMPLETED","enrollment_count":7026,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT05557487","title":"Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration","phase":"","overall_status":"RECRUITING","enrollment_count":6618,"lead_sponsor_name":"Gee-Chen Chang","has_results":false},{"nct_id":"NCT03576157","title":"Kilkari Impact Evaluation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5095,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT06266780","title":"Impact Evaluation of a Targeted mHealth Intervention to Improve Uptake of Postpartum Contraception in Kenya","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4190,"lead_sponsor_name":"Jacaranda Health","has_results":false},{"nct_id":"NCT04411511","title":"COVID-19, Obesity and Lifestyle in Children","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT03640546","title":"Healthy Marriage and Responsible Fatherhood Grant Program With Phoenix House of New York","phase":"","overall_status":"UNKNOWN","enrollment_count":3825,"lead_sponsor_name":"Phoenix House Foundation, Inc.","has_results":false},{"nct_id":"NCT06766396","title":"Predictors of PPIUCD Discontinuation at Two Years: A Clinical Study in Pakistan","phase":"NA","overall_status":"COMPLETED","enrollment_count":3400,"lead_sponsor_name":"Services Institute of Medical Sciences, Pakistan","has_results":false},{"nct_id":"NCT04208191","title":"Quality Improvement Project for Maternal Health and Family Planning Services in Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":3354,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03081195","title":"SMART Africa (Strengthening Mental Health Research and Training)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3117,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06496945","title":"Assessing the Impact of DAy Programs on Individuals Living with Dementia and Their Family/friend Caregivers","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"York University","has_results":false},{"nct_id":"NCT04693182","title":"Health Promoting Work Schedules: The Effect of Abolishing Quick Returns","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT03058549","title":"Impact Evaluation of Family Expectations: A Program to Strengthen the Relationships of Disadvantaged Expectant Couples","phase":"NA","overall_status":"COMPLETED","enrollment_count":2640,"lead_sponsor_name":"Public Strategies","has_results":false},{"nct_id":"NCT05503992","title":"Evaluating the Efficacy of Using a Digital Consumption Management Tool for Family Planning in Zambia","phase":"NA","overall_status":"COMPLETED","enrollment_count":2523,"lead_sponsor_name":"Boston University","has_results":false},{"nct_id":"NCT04092530","title":"Linking Inter-professional Newborn and Contraception Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":2518,"lead_sponsor_name":"Rush University Medical Center","has_results":true},{"nct_id":"NCT05678543","title":"Danish Diabetes Birth Registry 2","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT03888495","title":"Promoting Female Empowerment at the Household Level Among Couples in Ibadan, Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":2472,"lead_sponsor_name":"University of Ibadan","has_results":false},{"nct_id":"NCT07406113","title":"MEOP - Multidimensional Evaluations in Oncological Psychiatry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04411420","title":"Improving Veteran Access to Integrated Management of Back Pain","phase":"NA","overall_status":"COMPLETED","enrollment_count":1817,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT04065867","title":"Use ICT to Promote Family Well-being in Hong Kong","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04599218","title":"MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1586,"lead_sponsor_name":"Ardeshir Rastinehad","has_results":false},{"nct_id":"NCT05275413","title":"mHealth Intervention to Reduce Maternal Postnatal Depression and Promote Family Health","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1578,"lead_sponsor_name":"The Hong Kong Polytechnic University","has_results":false},{"nct_id":"NCT04081441","title":"Impacts of Clean Cookstoves and Empowerment Training on Women's Health in Refugee Settings","phase":"NA","overall_status":"COMPLETED","enrollment_count":1555,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT03881397","title":"Youth Health and Social Media","phase":"NA","overall_status":"COMPLETED","enrollment_count":1520,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT06450756","title":"Effect of Male Involvement in Family Planning Education on Contraceptive Use","phase":"NA","overall_status":"COMPLETED","enrollment_count":1496,"lead_sponsor_name":"Jimma University","has_results":false},{"nct_id":"NCT06923189","title":"Efficacy Testing of a Multi-Level Family Planning Intervention","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1464,"lead_sponsor_name":"Boston College","has_results":false},{"nct_id":"NCT05461521","title":"Improving FAMily Members' Experience in the ICU","phase":"","overall_status":"COMPLETED","enrollment_count":1346,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03846323","title":"Liberalization of Visiting Policies in ICU for Reducing High Risk of Post-traumatic Stress Disorder","phase":"NA","overall_status":"COMPLETED","enrollment_count":1289,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07240571","title":"Randomized Controlled Trial of a Family-focused Intervention for Caregivers and Young Adolescents (Phase 3 of FLOURISH)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1280,"lead_sponsor_name":"University of Klagenfurt","has_results":false},{"nct_id":"NCT04364282","title":"Stay In Treatment for Pediatric Weight Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":1216,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT06020027","title":"Water is K'é: Multi-level Intervention to Promote Healthy Beverage Choices Among Navajo Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1160,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04449978","title":"TARGet Kids! COVID-19 Study of Children and Families","phase":"","overall_status":"COMPLETED","enrollment_count":1145,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT04206527","title":"Improving Person-Centered Care for Family Planning in India","phase":"NA","overall_status":"COMPLETED","enrollment_count":1104,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03697421","title":"Montefiore Medical Center Healthy Marriage and Relationship Education Program","phase":"","overall_status":"COMPLETED","enrollment_count":1029,"lead_sponsor_name":"Montefiore Medical Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}